Skip to main content
Listen in: the latest news on Biosimilars! Listen to our new Coffee with ClearScript for the latest news on Biosimilars!

The clear choice in pharmacy benefit management.

Insights Archive

Filter by:

Drug Pipeline – Blue pills traveling through a sorting machine, a green pill stands out from the rest.

May 30, 2023

First in a new class

An estimated 8 million adults in the U.S. have psoriasis. Last month, the FDA approved Sotyktu (deucravacitinib), the first in a new class of oral medication to treat plaque psoriasis. Will this new product be revolutionary or evolutionary when it comes to plaque psoriasis therapy?

Drug Pipeline – Blue pills traveling through a sorting machine, a yellow pill stands out from the rest.

May 30, 2023

Are you watching this?

Alzheimer’s drug pipeline news: Biogen Inc. in partnership with Eisai Co. has released encouraging data about their new anti-amyloid monoclonal antibody therapy (lecanemab) currently in clinical trials.

Drug Pipeline – Blue pills traveling through a sorting machine, a red pill stands out from the rest.

May 8, 2023

The most expensive medicine in the world

Remarkably, 94% of participants in the supporting study who received Hemgenix were able to discontinue use of intravenous FIX infusions. This is an important consideration since FIX infusion therapy can cost of approximately $500,000–$750,000 per year.

Drug Pipeline – Blue pills traveling through a sorting machine, a yellow pill stands out from the rest.

December 8, 2022

Treatments for Rare Diseases

Currently, a significant proportion of the pharmaceutical development pipeline is represented by drugs used to treat rare diseases and, increasingly, gene therapies. For example, 44 drugs in ClearScript’s Brand Pipeline Forecast are used to treat rare diseases and are up for approval in the upcoming six months.